Excelsior Sciences secures $95 million to revolutionize drug discovery by replacing human chemists with AI-powered robots that break down FDA-approved molecules into 'smart bloccs' and reassemble them into new pharmaceutical compounds, promising faster and cheaper development while reshoring manufacturing to the US.
Valthos emerges from stealth with $30 million from OpenAI and top venture firms to build AI systems that detect biological threats in real-time, promising to slash response times from months to hours using frontier artificial intelligence technology.
Anthropic launches Claude for Life Sciences, its first specialized AI platform for the sector, promising to slash research tasks from days to minutes by integrating with scientific tools like PubMed and Benchling to accelerate discovery from literature reviews to regulatory submissions.
Cortical Labs launches CL1, the world's first commercial biological computer that harnesses 800,000 lab-grown human neurons to process data with submillisecond response times, offering a $35,000 energy-efficient alternative to traditional computing for pharmaceutical, financial, and AI research applications.
Billionaire Mark Cuban harnesses OpenAI's Sora platform to generate AI videos of himself promoting his pharmaceutical company Cost Plus Drugs, with the viral clips featuring him delivering promotional messages and dancing garnering tens of thousands of views as a cost-free marketing experiment.
Google enhances its Jules AI coding assistant with new command line tools and API support, while Nvidia introduces a revolutionary 4-bit training format that cuts AI training costs, and MIT researchers use generative AI to dramatically accelerate antibiotic discovery from years to much shorter timeframes.
AstraZeneca strikes a massive $555 million partnership with Algen Biotechnologies, combining cutting-edge AI platform 'AlgenBrain' with CRISPR gene technology to revolutionize drug discovery for chronic inflammatory diseases and unlock next-generation immunology therapies.
AI agents powered by large language models now assist scientists with research tasks like data curation and literature reviews, while new collaborative systems mimic medical teams to analyze drug trials and identify unexpected therapeutic effects, though current technology still requires human oversight due to reliability limitations.
MIT and McMaster University researchers use AI to discover enterololin, a revolutionary narrow-spectrum antibiotic that targets harmful gut bacteria causing Crohn's disease while preserving beneficial microbes, showing promising results in mouse studies and advancing toward human trials.
RNA structure prediction remains far behind protein prediction as AlphaFold3 struggles with RNA's extreme flexibility, with only 7,759 RNA structures mapped versus 216,212 proteins, though most RNA therapeutics like mRNA vaccines rely on secondary structure which scientists can now predict with high accuracy.